Predictors of atrial mechanical sensing and atrioventricular synchrony with a leadless ventricular pacemaker: Results from the MARVEL 2 Study.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
12 2020
Historique:
received: 22 04 2020
revised: 08 07 2020
accepted: 20 07 2020
pubmed: 28 7 2020
medline: 30 9 2021
entrez: 28 7 2020
Statut: ppublish

Résumé

The MARVEL (Micra Atrial TRacking Using a Ventricular AccELerometer) 2 study assessed the efficacy of atrioventricular (AV) synchronous pacing with a Micra leadless pacemaker. Average atrioventricular synchrony (AVS) was 89.2%. Previously, low amplitude of the Micra-sensed atrial signal (A4) was observed to be a factor of low AVS. The purpose of this study was to identify predictors of A4 amplitude and high AVS. We analyzed 64 patients enrolled in MARVEL 2 who had visible P waves on electrocardiogram for assessing A4 amplitude and 40 patients with third-degree AV block for assessing AVS at rest. High AVS was defined as >90% correct atrial-triggered ventricular pacing. The association between clinical factors and echocardiographic parameters with A4 amplitude was investigated using a multivariable model with lasso variable selection. Variables associated with A4 amplitude together with premature ventricular contraction burden, sinus rate, and sinus rate variability (standard deviation of successive differences of P-P intervals [SDSD]) were assessed for association with AVS. In univariate analysis, low A4 amplitude was inversely related to atrial function assessed by E/A ratio and e'/a' ratio, and was directly related to atrial contraction excursion (ACE) and atrial strain (Ɛa) on echocardiography (all P ≤.05). The multivariable lasso regression model found coronary artery bypass graft history, E/A ratio, ACE, and Ɛa were associated with low A4 amplitude. E/A ratio and SDSD were multivariable predictors of high AVS, with >90% probability if E/A <0.94 and SDSD <5 bpm. Clinical parameters and echocardiographic markers of atrial function are associated with A4 signal amplitude. High AVS can be predicted by E/A ratio <0.94 and low sinus rate variability at rest.

Sections du résumé

BACKGROUND
The MARVEL (Micra Atrial TRacking Using a Ventricular AccELerometer) 2 study assessed the efficacy of atrioventricular (AV) synchronous pacing with a Micra leadless pacemaker. Average atrioventricular synchrony (AVS) was 89.2%. Previously, low amplitude of the Micra-sensed atrial signal (A4) was observed to be a factor of low AVS.
OBJECTIVE
The purpose of this study was to identify predictors of A4 amplitude and high AVS.
METHODS
We analyzed 64 patients enrolled in MARVEL 2 who had visible P waves on electrocardiogram for assessing A4 amplitude and 40 patients with third-degree AV block for assessing AVS at rest. High AVS was defined as >90% correct atrial-triggered ventricular pacing. The association between clinical factors and echocardiographic parameters with A4 amplitude was investigated using a multivariable model with lasso variable selection. Variables associated with A4 amplitude together with premature ventricular contraction burden, sinus rate, and sinus rate variability (standard deviation of successive differences of P-P intervals [SDSD]) were assessed for association with AVS.
RESULTS
In univariate analysis, low A4 amplitude was inversely related to atrial function assessed by E/A ratio and e'/a' ratio, and was directly related to atrial contraction excursion (ACE) and atrial strain (Ɛa) on echocardiography (all P ≤.05). The multivariable lasso regression model found coronary artery bypass graft history, E/A ratio, ACE, and Ɛa were associated with low A4 amplitude. E/A ratio and SDSD were multivariable predictors of high AVS, with >90% probability if E/A <0.94 and SDSD <5 bpm.
CONCLUSION
Clinical parameters and echocardiographic markers of atrial function are associated with A4 signal amplitude. High AVS can be predicted by E/A ratio <0.94 and low sinus rate variability at rest.

Identifiants

pubmed: 32717315
pii: S1547-5271(20)30682-2
doi: 10.1016/j.hrthm.2020.07.024
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03752151']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2037-2045

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL128595
Pays : United States

Informations de copyright

Copyright © 2020 The Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Christophe Garweg (C)

University Hospitals Leuven, Leuven, Belgium. Electronic address: christophe.garweg@uzleuven.be.

Surinder Kaur Khelae (SK)

Institut Jantung Negara, Kuala Lumpur, Malaysia.

Clemens Steinwender (C)

Kepler University Hospital Linz, Linz, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria.

Joseph Yat Sun Chan (JYS)

Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong.

Philippe Ritter (P)

Hôpital Haut-Lévêque-CHU de Bordeaux, Pessac, France.

Jens Brock Johansen (JB)

Odense University Hospital, Odense, Denmark.

Venkata Sagi (V)

Medical Center, Jacksonville, Florida.

Laurence M Epstein (LM)

North Shore University Hospital, Manhasset, New York.

Jonathan P Piccini (JP)

Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina.

Mario Pascual (M)

Baptist Hospital, Miami, Florida.

Lluis Mont (L)

Institut Clinic Cardiovascular (ICCV), Hospital Clínic, Universitat de Barcelona, Catalonia, Barcelona, Spain.

Rik Willems (R)

University Hospitals Leuven, Leuven, Belgium.

Todd Sheldon (T)

Medtronic, Inc., Mounds View, Minnesota.

Vincent Splett (V)

Medtronic, Inc., Mounds View, Minnesota.

Kurt Stromberg (K)

Medtronic, Inc., Mounds View, Minnesota.

Nicole Wood (N)

Medtronic, Inc., Mounds View, Minnesota.

Larry Chinitz (L)

NYU Langone Medical Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH